Zacks Investment Research downgraded Alkermes Plc (NASDAQ:ALKS) to Sell in a statement released earlier today.
- Updated: October 14, 2016
Boasting a price of $42.77, Alkermes Plc (NASDAQ:ALKS) traded -2.67% lower on the day. With the last stock price close down -3.23% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Alkermes Plc has recorded a 50-day average of $46.82 and a two hundred day average of $44.13. Volume of trade was down over the average, with 551,832 shares of ALKS changing hands under the typical 778,949
Zacks Investment Research has downgraded Alkermes Plc (NASDAQ:ALKS) to Sell in a statement released on 10/14/2016.
On 10/4/2016, Leerink Swann released a statement for Alkermes Plc (NASDAQ:ALKS) bumped up the target price from $0.00 to $57.00 that suggested an upside of 0.21%.
Recent Performance Chart
Alkermes Plc has with a one year low of $27.14 and a one year high of $80.71 and has a market capitalization of $0.
A total of 10 brokerages have released a report on Alkermes Plc. Two brokerages rating the company a strong buy, 2 brokers rating the stock a buy, 6 brokers rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell with a consensus target price of $44.40.
General Information About Alkermes Plc (NASDAQ:ALKS)
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. Its products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. Its product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.